Edwards Lifesciences keep cataract following 4Q report
Regulators too late very last time.THE ANALYSIS: Jefferies analyst Raj Denhoy prominent with the purpose of the fourth-quarter revenue fell roughly speaking $17 million underneath both what did you say? he and the consensus was expecting.He thought procedure volume weakness modish southern Europe impacted both surgical and transcatheter valves and may well persist ended the subsequently pair quarters, but growth must normalize modish the back semi of the time.Denhoy thought shares may possibly come to pass down Friday for the reason that the companys quarter was a unimportant messy, and particular investors may possibly come to pass taking profits next topical rally dressed in share prices.SHARE ACTION: Down 11 percent, otherwise $9.09, to $71.